The leading players operating in the global autologous cell therapy market are Vericel Corporation, BioTime, Inc., Pharmicell Co., BrainStorm Cell Therapeutics, Opexa Therapeutics, Inc, Pharmicell Co., Inc. These companies are expected to focus on mergers and acquisitions to enter local markets, observes Transparency Market Research. Furthermore, efforts to establish subsidiaries and manufacturing centers in emerging economies are also expected to make the global market exceptionally competitive in the coming few years.
According to the research report, the global autologous cell therapy market is expected to be worth US$23.7 bn by the end of 2024 as compared to US$3.8 bn in 2015. During the forecast period of 2016 and 2024, the global market is estimated to exhibit a CAGR of 21.9%.
Global Autologous Cell Therapy Market: Overview
Autologous cell therapy refers to infusion or transfer of human tissue or cells back to the same person for treating a diseased part. For the same purpose, stem cells are removed from the patient, harvested, cultured, and once again transplanted to the same person. The purpose of this method is to reduce the chances of rejection to the treatment by the body. Furthermore, autologous cell therapy does not even require immunosuppression. The growing number of cancer patients have triggered a significant demand for autologous cell therapy. According to the research report, the global autologous cell therapy market projected to reach a valuation of US$23.7 bn by the end of 2024 as compared to US$3.8 bn in 2015. During the forecast period of 2016 and 2024, the global market is estimated to exhibit a CAGR of 21.9%.
Browse Global Strategic Business Report:
Global Autologous Cell Therapy Market: Drivers and Trends
The market overview section comprises impact factors such as drivers, restraints, and opportunities for the global autologous cell therapy market. These factors would aid the stakeholders in establishing a strong foothold in the global autologous cell therapy market. Furthermore, the market overview section comprises key industry events, product overview, market attractiveness analysis and emerging trend in the autologous cell therapy market. The market attractiveness analysis provides a graphical view comparing the growth and market dynamics in various segments and country wise to identify the most attractive market.
Global Autologous Cell Therapy Market: Segmentation
The autologous cell therapy market has been segmented as source, application, end-user and geography. Based on source, the market has been segmented into bone marrow, epidermis and others. Likewise, on basis of application the market has been categorized into neurology, orthopedic, cancer, wound healing, CVD, autoimmune, and others. Hospitals, ambulatory centers and research centers are included into the market by end-user.
Global Autologous Cell Therapy Market: Regional Outlook
Geographically, the autologous cell therapy market has been categorized into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Moreover, analysis for the major countries comprising U.S. Canada, Germany, U.K., France, Switzerland, Spain, Japan, China, Brazil, Mexico, South Africa and Saudi Arabia have also been provided in the report. A detailed qualitative analysis of the factors responsible for driving and restraining the growth of the autologous cell therapy market in various regions has been provided in this section.
This report also includes various ups and downs about particular country or geography that has impacted the overall market globally. The report provides a detailed outline/blueprint of the autologous cell therapy market globally that will assist new companies in establishing their presence and market players in expanding their market share in the market.
Key Players Mentioned in the Report are:
The report concludes with the company profile section which includes company overview, financial overview, SWOT analysis, product portfolio, business strategies and recent developments for market players. The major players that are profiled in the report include BIOTIME, INC., BrainStorm Cell Therapeutics, Caladrius Biosciences, Inc., Vericel Corporation, Pharmicell Co., Inc., TiGenix N.V., Fibrocell Science, Inc. and Opexa Therapeutics, Inc. among others.
Download Exclusive Brochure of This Report :
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453